Search

everythinglearnresearchcommunity

for

Search:↓

Selumetinib causes fewer and less severe skin issues in children than binimetinib.

Canagliflozin helps overcome progestin resistance in certain endometrial cancer cells.

Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.

PI3Kδ inhibition may effectively treat cutaneous chronic graft-versus-host disease.

Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.

Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.

Tofacitinib may be safe and effective for treating certain skin conditions in children.

Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.

Tofacitinib is effective and safe for treating alopecia areata with a good drug survival rate.

Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.

Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.

RNA aptamers can specifically block FGF5-related cell growth, potentially treating related diseases or hair disorders.

Tofacitinib effectively treated severe alopecia areata in a 14-year-old girl.

FGF signaling is a promising target for developing treatments for wounds, metabolic diseases, and cancer.

BLZ-100 is safe for use in skin cancer surgery and may help identify cancerous tissue.

Kanglaite injection with chemotherapy improves treatment and reduces side effects for advanced lung cancer.

Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.

Effective management of side effects is crucial for safe use of sacituzumab govitecan in advanced breast cancer treatment.

The new gel formula could improve the delivery of a hair loss treatment through the skin and might be an alternative to taking it by mouth.

CTP-543 is generally safe for treating alopecia areata.

Curcumin, EGCG, barringtozenol, and finasteride are effective VEGFR inhibitors.

Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.

Dual-targeted therapy is effective and safe for difficult-to-treat inflammatory bowel disease.

A topical BRAF inhibitor, vemurafenib, can speed up wound healing and promote hair growth, especially in diabetic patients.

Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.

Upadacitinib may help regrow hair in children with alopecia areata and is generally safe.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

Upadacitinib effectively treated a patient with multiple inflammatory conditions.

Compound 6 is a promising candidate for better wound healing.